Xencor Inc (XNCR)

$11.99 -0.12 (-0.99%)
Market Cap 863.35M
Revenue (ttm) 110.49M
Net Income (ttm) -232.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -210.53%
Debt to Equity Ratio 0.00
Volume 471,200
Avg Vol 732,740
Day's Range N/A - N/A
Shares Out 71.41M
Stochastic %K 12%
Beta 0.97
Analysts Strong Sell
Price Target $28.83

Company Profile

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab th...

Industry: Biotechnology
Sector: Healthcare
Phone: 626 305 5900
Address:
465 North Halstead Street, Suite 200, Pasadena, United States
Breck100
Breck100 Feb. 3 at 5:34 PM
$XNCR 1/9/26 Morning Notes
0 · Reply
RubyReturns
RubyReturns Jan. 19 at 8:17 PM
$XNCR Biotech with actual science, rerates on data not hype
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 19 at 1:01 PM
$XNCR Current Stock Price: $12.78 Contracts to trade: $10 XNCR Feb 20 2026 Call Entry: $4.00 Exit: $6.09 ROI: 52% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Estimize
Estimize Jan. 19 at 12:03 PM
Wall St is expecting -0.60 EPS for $XNCR Q4 [Reporting 03/04 AMC] http://www.estimize.com/intro/xncr?chart=historical&metric_name=eps&utm_c
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 15 at 1:43 AM
$XNCR Current Stock Price: $14.44 Contracts to trade: $15 XNCR Jan 16 2026 Call Entry: $0.18 Exit: $0.31 ROI: 71% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 13 at 1:16 PM
$XNCR RSI: 36.52, MACD: -0.4742 Vol: 0.85, MA20: 15.25, MA50: 15.54 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Wisenheimer
Wisenheimer Jan. 6 at 5:24 PM
$XNCR back to $8 on the $ZBIO decline :((
1 · Reply
IN0V8
IN0V8 Dec. 26 at 4:53 PM
$XNCR Buying Opportunity Truist Securities initiates coverage with buy rating; PT $29
0 · Reply
AlternateReality
AlternateReality Dec. 26 at 1:57 PM
$XNCR The environment increasingly favors disciplined operators instead of aggressive storytellers. Efficiency initiatives must translate into measurable productivity. Transparency improvements could narrow valuation discounts. Execution quality will determine whether momentum is sustainable.
0 · Reply
JarvisFlow
JarvisFlow Dec. 17 at 6:01 PM
Barclays has updated their rating for Xencor ( $XNCR ) to Overweight with a price target of 26.
0 · Reply
Latest News on XNCR
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones

Jan 8, 2026, 8:01 AM EST - 26 days ago

Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones

Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942

Jan 1, 2026, 7:14 AM EST - 4 weeks ago

Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942

Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies

Dec 9, 2025, 7:00 AM EST - 2 months ago

Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies

Xencor to Participate at Upcoming Investor Conferences

Nov 10, 2025, 4:01 PM EST - 3 months ago

Xencor to Participate at Upcoming Investor Conferences

Xencor Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:01 PM EST - 3 months ago

Xencor Reports Third Quarter 2025 Financial Results

Xencor, Inc. (XNCR) Discusses Initial Phase I Dose Escalation Results for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Transcript

Oct 24, 2025, 5:37 PM EDT - 3 months ago

Xencor, Inc. (XNCR) Discusses Initial Phase I Dose Escalation Results for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Transcript

Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma

Oct 24, 2025, 12:30 PM EDT - 3 months ago

Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma

Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

Oct 21, 2025, 8:01 AM EDT - 3 months ago

Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 14, 2025, 12:45 PM EDT - 4 months ago

Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release

Sep 19, 2025, 5:35 PM EDT - 4 months ago

Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release

Xencor Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 4:01 PM EDT - 6 months ago

Xencor Reports Second Quarter 2025 Financial Results

Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors

Jul 31, 2025, 4:01 PM EDT - 6 months ago

Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors

Xencor Reports First Quarter 2025 Financial Results

May 7, 2025, 4:01 PM EDT - 9 months ago

Xencor Reports First Quarter 2025 Financial Results

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

Apr 29, 2025, 4:01 PM EDT - 10 months ago

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

Xencor Appoints Todd Simpson to Board of Directors

Mar 13, 2025, 4:01 PM EDT - 11 months ago

Xencor Appoints Todd Simpson to Board of Directors

Xencor Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 8:01 AM EST - 1 year ago

Xencor Reports Fourth Quarter and Full Year 2024 Financial Results

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

Feb 18, 2025, 10:20 AM EST - 1 year ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

ARWR AUB CRK CYTK EXE KRYS MARA

Xencor: Plamotamab NHL Data Leads To RA Program Advancement

Nov 22, 2024, 2:00 PM EST - 1 year ago

Xencor: Plamotamab NHL Data Leads To RA Program Advancement

Xencor Reports Third Quarter 2024 Financial Results

Nov 6, 2024, 4:01 PM EST - 1 year ago

Xencor Reports Third Quarter 2024 Financial Results

Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease

Nov 4, 2024, 7:00 AM EST - 1 year ago

Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease

Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases

Oct 10, 2024, 8:09 AM EDT - 1 year ago

Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases

Xencor Announces Upcoming Change to Board of Directors

Oct 4, 2024, 8:01 AM EDT - 1 year ago

Xencor Announces Upcoming Change to Board of Directors

Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 12, 2024, 4:01 PM EDT - 1 year ago

Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Xencor: Vudalimab Development Along With Hidden Gem Candidate

Sep 12, 2024, 8:16 AM EDT - 1 year ago

Xencor: Vudalimab Development Along With Hidden Gem Candidate

Xencor Announces Pricing of $175 Million Public Offering of Common Stock

Sep 11, 2024, 6:31 AM EDT - 1 year ago

Xencor Announces Pricing of $175 Million Public Offering of Common Stock

Xencor Announces Proposed Public Offering of Common Stock

Sep 10, 2024, 4:01 PM EDT - 1 year ago

Xencor Announces Proposed Public Offering of Common Stock

Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

Sep 9, 2024, 7:31 AM EDT - 1 year ago

Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024

Sep 6, 2024, 8:01 AM EDT - 1 year ago

Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024

Xencor Reports Second Quarter 2024 Financial Results

Aug 5, 2024, 4:01 PM EDT - 1 year ago

Xencor Reports Second Quarter 2024 Financial Results

Xencor Regains CD20 x CD3 Bispecific T-Cell Engager

Jun 13, 2024, 8:01 AM EDT - 1 year ago

Xencor Regains CD20 x CD3 Bispecific T-Cell Engager

Xencor Reports First Quarter 2024 Financial Results

May 9, 2024, 4:09 PM EDT - 1 year ago

Xencor Reports First Quarter 2024 Financial Results

Xencor Appoints Bart Cornelissen as Chief Financial Officer

Apr 9, 2024, 8:01 AM EDT - 1 year ago

Xencor Appoints Bart Cornelissen as Chief Financial Officer

Xencor to Present at Upcoming Investor Conferences

Feb 28, 2024, 4:01 PM EST - 2 years ago

Xencor to Present at Upcoming Investor Conferences

Xencor, Inc. (XNCR) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 12:35 AM EST - 2 years ago

Xencor, Inc. (XNCR) Q4 2023 Earnings Call Transcript

Xencor Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 27, 2024, 4:01 PM EST - 2 years ago

Xencor Reports Fourth Quarter and Full Year 2023 Financial Results

Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update

Feb 20, 2024, 4:31 PM EST - 2 years ago

Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update

Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 4:01 PM EST - 2 years ago

Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy

Jan 2, 2024, 8:01 AM EST - 2 years ago

Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy

20 favorite small-cap stocks for 2024 among Wall Street analysts

Dec 26, 2023, 12:18 PM EST - 2 years ago

20 favorite small-cap stocks for 2024 among Wall Street analysts

ARLO CPRX DGII DVAX GPRE HLX IRWD

Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 21, 2023, 4:01 PM EST - 2 years ago

Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference

Xencor, Inc. (XNCR) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 8:29 AM EST - 2 years ago

Xencor, Inc. (XNCR) Q3 2023 Earnings Call Transcript

Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million

Nov 7, 2023, 4:01 PM EST - 2 years ago

Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million

Xencor Reports Third Quarter 2023 Financial Results

Nov 7, 2023, 4:01 PM EST - 2 years ago

Xencor Reports Third Quarter 2023 Financial Results

Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting

Nov 3, 2023, 12:01 PM EDT - 2 years ago

Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting

Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023

Oct 31, 2023, 4:01 PM EDT - 2 years ago

Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023

Xencor: Data In Early 2024 Could Bring Shareholder Value

Oct 27, 2023, 11:56 AM EDT - 2 years ago

Xencor: Data In Early 2024 Could Bring Shareholder Value

Xencor Announces Planned Retirement of Chief Financial Officer John Kuch

Oct 26, 2023, 8:01 AM EDT - 2 years ago

Xencor Announces Planned Retirement of Chief Financial Officer John Kuch

Xencor: A Mid-Stage Clinical Company With Falling Losses

Oct 20, 2023, 11:02 PM EDT - 2 years ago

Xencor: A Mid-Stage Clinical Company With Falling Losses

Xencor to Present Multiple Posters at the SITC Annual Meeting

Sep 27, 2023, 9:01 AM EDT - 2 years ago

Xencor to Present Multiple Posters at the SITC Annual Meeting

Xencor Appoints Barbara J. Klencke, M.D.

Sep 19, 2023, 4:01 PM EDT - 2 years ago

Xencor Appoints Barbara J. Klencke, M.D.

Breck100
Breck100 Feb. 3 at 5:34 PM
$XNCR 1/9/26 Morning Notes
0 · Reply
RubyReturns
RubyReturns Jan. 19 at 8:17 PM
$XNCR Biotech with actual science, rerates on data not hype
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 19 at 1:01 PM
$XNCR Current Stock Price: $12.78 Contracts to trade: $10 XNCR Feb 20 2026 Call Entry: $4.00 Exit: $6.09 ROI: 52% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Estimize
Estimize Jan. 19 at 12:03 PM
Wall St is expecting -0.60 EPS for $XNCR Q4 [Reporting 03/04 AMC] http://www.estimize.com/intro/xncr?chart=historical&metric_name=eps&utm_c
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 15 at 1:43 AM
$XNCR Current Stock Price: $14.44 Contracts to trade: $15 XNCR Jan 16 2026 Call Entry: $0.18 Exit: $0.31 ROI: 71% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 13 at 1:16 PM
$XNCR RSI: 36.52, MACD: -0.4742 Vol: 0.85, MA20: 15.25, MA50: 15.54 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Wisenheimer
Wisenheimer Jan. 6 at 5:24 PM
$XNCR back to $8 on the $ZBIO decline :((
1 · Reply
IN0V8
IN0V8 Dec. 26 at 4:53 PM
$XNCR Buying Opportunity Truist Securities initiates coverage with buy rating; PT $29
0 · Reply
AlternateReality
AlternateReality Dec. 26 at 1:57 PM
$XNCR The environment increasingly favors disciplined operators instead of aggressive storytellers. Efficiency initiatives must translate into measurable productivity. Transparency improvements could narrow valuation discounts. Execution quality will determine whether momentum is sustainable.
0 · Reply
JarvisFlow
JarvisFlow Dec. 17 at 6:01 PM
Barclays has updated their rating for Xencor ( $XNCR ) to Overweight with a price target of 26.
0 · Reply
Sambong
Sambong Dec. 15 at 8:24 PM
$XNCR i have my 👀 on you..
0 · Reply
RunnerSignals
RunnerSignals Nov. 25 at 8:28 PM
$MARA $MNKD $NUVB $VFS $XNCR Big upside alerts for traders https://stocksrunner.com/news/2025-11-25-stock-upgrades-today-see-wall-street-boost-confidence
0 · Reply
JarvisFlow
JarvisFlow Nov. 24 at 6:05 PM
Truist Securities updates rating for Xencor ( $XNCR ) to Buy, target set at 29.
0 · Reply
Swing_Tradr
Swing_Tradr Nov. 24 at 3:27 PM
$XNCR looking good this morning and getting closer to TradrSense Pro’s price target of $18.78. Original callout from 11/05/2025. Check it out 👉 https://swingtradr/
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 14 at 4:50 PM
$XNCR Share Price: $15.00 Contract Selected: May 15, 2026 $15 Calls Buy Zone: $0.65 – $0.80 Target Zone: $1.08 – $1.32 Potential Upside: 57% ROI Time to Expiration: 181 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
macroaxis
macroaxis Nov. 10 at 2:41 AM
$XNCR – Urgent Alert: Xencor Max Pain Price Is Dropping – Watch for Potential Downside Risks https://www.macroaxis.com/stock-options/XNCR/Xencor-Inc?utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 10:40 PM
JP Morgan updates rating for Xencor ( $XNCR ) to Overweight, target set at 20 → 18.
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 4:31 PM
RBC Capital has adjusted their stance on Xencor ( $XNCR ), setting the rating to Outperform with a target price of 18 → 19.
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 2:52 PM
Cantor Fitzgerald has updated their rating for Xencor ( $XNCR ) to Overweight with a price target of 42.
0 · Reply